First Half 2026 Recap - Cardiology

Although recent months have seen a substantial uptick in approvals, the first half of 2026 was a relatively quiet period for the US Food and Drug Administration (FDA). However, this dearth of regulatory updates was balanced out by a significant number of clinical trials reaching statistical significance in everything from heart failure to atherosclerotic cardiovascular disease (ASCVD), with major readouts presented at a slew of conferences across the country.